Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
- Investors can access the conference call via webcast on Marinus’ website at ir.marinuspharma.com/events-and-presentations.
- None.
Participants may access the conference call via webcast on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20231024565228/en/
Investors
Jim DeNike
Senior Director, Investor Relations
Marinus Pharmaceuticals, Inc.
jdenike@marinuspharma.com
Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
FAQ
When will Marinus Pharmaceuticals release its financial results for Q3 2023?
What time is the conference call scheduled for?
How can investors access the conference call?